Vertex Pharmaceuticals (VRTX), which probably didn't need any more catalysts, gets a lift from...

|About: Vertex Pharmaceuticals Inco... (VRTX)|By:, SA News Editor

Vertex Pharmaceuticals (VRTX), which probably didn't need any more catalysts, gets a lift from upgrades at both Canaccord (Buy from Hold) and Goldman (Neutral from Sell). Canaccord says "the CF corrector discovery platform" has been validated and the "likelihood for trial success and uptake" has increased. Goldman admits to being "completely wrong" about the prospects for VRTX's CF combo platform. Price targets: $96 at Canaccord and $86 at Goldman. Shares +62% premarket.